Endo Pharmaceuticals agreed to pay US$2.3 million to 18 states late last week, settling allegations that the drugmaker paid a competitor to keep a generic version of pain relief drug Lidoderm (Lidocaine patch 5%) off the market.
Endo Pharmaceuticals agreed to pay US$2.3 million to 18 states late last week, settling allegations that the drugmaker paid a competitor to keep a generic version of pain relief drug Lidoderm off the market.
Utah and the other states had accused Endo of entering into a reverse-payment agreement (a pay-for-delay agreement) with Watson Laboratories to obstruct generic competition to Lidoderm for more than a year.
“At the time of the Lidoderm agreement, Lidoderm was Endo’s most important branded prescription drug product. In 2011, Endo generated more than $825 million from its branded Lidoderm patches, comprising 30% of Endo’s total annual revenues,” alleged the states.
According to the claim, Endo paid Watson, which is now a Teva subsidiary, to not compete with Endo’s “lucrative” Lidoderm franchise.
In the separately filed settlement agreement, Endo denied that it engaged in any wrongful or unlawful conduct. Under the settlement, the drugmaker agreed to pay US$2.3 million to the states.
Full Content: Lifes Cience Preview
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
BHP Unveils £31bn Mining Megamerger Proposal with Anglo American
Apr 25, 2024 by
nhoch@pymnts.com
ByteDance Prefers Shutdown Over Sale of TikTok Amid US Ban Threats
Apr 25, 2024 by
CPI
FCC Votes to Restore Net Neutrality Rules
Apr 25, 2024 by
nhoch@pymnts.com
Apple Rejects Spotify’s Updated App Over In-App Pricing Disclosure
Apr 25, 2024 by
CPI
FCC Set to Reinstate Net Neutrality Rules Today
Apr 25, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI